KRAS mutated Low-Grade Serous Ovarian Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Despite being resistant to chemotherapy, low-grade serous ovarian cancer (LGSOC) typically develops in young women and has a fair chance of survival. KRAS and BRAF mutations, which are indicative of low-grade serous cancers, are more common than TP53 mutations, which are indicative of high-grade serous cancers. Most ovarian carcinomas (2-5%) and serous ovarian carcinomas (5-10%) are LGSC. Due to the rarity of this condition, there is a lack of data on its distribution, specific factors that influence how it develops, and descriptions of patients' experiences. Cancer therapeutics have evolved over the past two decades, moving from treating cancers based on their organ of origin (histologically agnostic), to their histology (histologically matched), and finally, to their molecular or genetic signature (tumour-agnostic).

Description

Despite being resistant to chemotherapy, low-grade serous ovarian cancer (LGSOC) typically develops in young women and has a fair chance of survival. KRAS and BRAF mutations, which are indicative of low-grade serous cancers, are more common than TP53 mutations, which are indicative of high-grade serous cancers. A KRAS/BRAF mutation is a positive prognostic indicator for women with low-grade serous ovarian cancer. In contrast to high-grade carcinoma, LGSOC is less frequently associated with TP53 alterations. KRAS mutations are uncommon in high-grade histology, but they are altered in 20 to 40% of LGSOC. Most serous ovarian cancers are classified as low- or high-grade serous carcinomas. The distinction between low-grade serous ovarian cancer (LGSOC) and high-grade disease, which is known to have a better prognosis for progression-free survival than high-grade disease, has clinical significance. However, LGSOC frequently avoids the effects of cytotoxic medications (4% response rate [RR]). It is essential to comprehend the tumour grade because of the molecular differences between low-grade and high-grade serous carcinoma.

KRAS mutated Low-Grade Serous Ovarian Cancer (Epidemiology)

Most ovarian carcinomas (2-5%) and serous ovarian carcinomas (5-10%) are LGSC. Due to the rarity of this condition, there is a lack of data on its distribution, specific factors that influence how it develops, and descriptions of patients' experiences. The second most common gynecologic malignancy in the US is cancer, which also accounts for the majority of deaths from gynecologic cancer. Although it was once thought that low-grade and high-grade serous tumours were one continuum, it is now clear that they are two separate entities. They grow in different ways, display different clinical behaviors, and ultimately have different prognoses. The clinical behavior and genetic environment of LGSC are distinct. Long-term survival, indolent progression, and relative chemo-resistance are traits of LGSC. Additionally, the disease is discovered earlier in life.

KRAS mutated Low-Grade Serous Ovarian Cancer -Current Market Size & Forecast Trends

The market for KRAS-mutated low-grade serous ovarian cancer (LGSOC) is expected to grow significantly through 2035, driven by advancements in targeted therapies and personalized medicine. While the broader LGSOC market was valued at approximately $179.6 million in 2023 and is projected to reach $363.7 million by 2034, the KRAS inhibitors market is set to grow rapidly, reaching $10 billion by 2032. Key developments, like Verastem Oncology's planned treatment launch for KRAS-mutant LGSOC in 2025, highlight the increasing focus on innovative treatments in this area.

Cancer therapeutics have evolved over the past two decades, moving from treating cancers based on their organ of origin (histologically agnostic), to their histology (histologically matched), and finally, to their molecular or genetic signature (tumour-agnostic). Rare malignancies, such as peritoneal, fallopian, and ovarian cancer-herein collectively referred to as ovarian cancer-are the last to benefit from this transformation due to their low incidence. All ovarian cancer histologies, including the common subtype, high-grade serous carcinoma, as well as the less common clear cell, low-grade serous, and endometrioid subtypes, continue to be treated with cytotoxic chemotherapy as the mainstay of care. Low-grade serous ovarian cancer accounts for up to 10% of cases and is characterized by poor response to chemotherapy, high oestrogen and progesterone receptor expression, and activating mutations in the MAPK pathway, which are present in 30-60% of cases. Unknown is the best first-line therapy for low-grade serous ovarian cancer. The main course of treatment for LGSC is surgery, and it is imperative to make every effort to leave a microscopic remnant in cases of metastatic disease. Adjuvant platinum-based chemotherapy is still the norm in LGSC despite the fact that it is comparatively chemo-resistant. Results are improved with hormonal maintenance therapy following adjuvant chemotherapy. Secondary cytoreductive surgery, chemotherapy, hormonal therapy, targeted therapy, and clinical trials are among the available treatments for disease recurrence. The treatment landscape in LGSOC is anticipated to change as a result of improvements in genomic research and targeted therapies.

Report Highlights

KRAS mutated Low-Grade Serous Ovarian Cancer - Current Market Trends

KRAS mutated Low-Grade Serous Ovarian Cancer - Current & Forecasted Cases across the G8 Countries

KRAS mutated Low-Grade Serous Ovarian Cancer - Market Opportunities and Sales Potential for Agents

KRAS mutated Low-Grade Serous Ovarian Cancer - Patient-based Market Forecast to 2035

KRAS mutated Low-Grade Serous Ovarian Cancer - Untapped Business Opportunities

KRAS mutated Low-Grade Serous Ovarian Cancer - Product Positioning Vis-a-vis Competitors' Products

KRAS mutated Low-Grade Serous Ovarian Cancer - KOLs Insight